China’s Ascendance as a Global Oncology Clinical Trials Epicenter: Navigating the 30-Day IND Pathway and "China Readiness"
Executive Overview Over the past decade, the global landscape of oncology clinical research has undergone a seismic shift, with the People’s Republic of China emerging as an indispensable nexus for…